Literature DB >> 17577050

A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza.

Marissa J Carter1.   

Abstract

Acute hypercytokinaemia represents an imbalance of pro-inflammatory and anti-inflammatory cytokines, and is believed to be responsible for the development of acute respiratory distress syndrome and multiple organ failure in severe cases of avian (H5N1) influenza. Although neuraminidase inhibitors are effective in treating avian influenza, especially if given within 48 h of infection, it is harder to prevent the resultant hypercytokinaemia from developing if the patient does not seek timely medical assistance. Steroids have been used for many decades in a wide variety of inflammatory conditions in which hypercytokinaemia plays a role, such as sepsis and viral infections, including severe acquired respiratory syndromes and avian influenza. However, to date, the results have been mixed. Part of the reason for the discrepancies might be the lack of understanding that low doses are required to prevent mortality in cases of adrenal insufficiency. Adrenal insufficiency, as defined in the sepsis/shock literature, is a plasma cortisol rise of at least 9 microg dl(-1) following a 250 microg dose of adrenocorticotropin hormone (ACTH), or reaching a plasma cortisol concentration of >25 microg dl(-1) following a 1-2 microg dose of ACTH. In addition, in the case of hypercytokinaemia induced by potent viruses, such as H5N1, systemic inflammation-induced, acquired glucocorticoid resistance is likely to be present. Adrenal insufficiency can be overcome, however, with prolonged (7-10 or more days) supraphysiological steroid treatment at a sufficiently high dose to address the excess activation of NF-kappaB, but low enough to avoid immune suppression. This is a much lower dose than has been typically used to treat avian influenza patients. Although steroids cannot be used as a monotherapy in the treatment of avian influenza, there might be a potential role for their use as an adjunct treatment to antiviral therapy if appropriate dosages can be determined. In this paper, likely mechanisms of adrenal insufficiency are discussed, drawing from a broad background of literature sources.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17577050     DOI: 10.1099/jmm.0.47124-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  31 in total

1.  Genomic profiling of tumor necrosis factor alpha (TNF-alpha) receptor and interleukin-1 receptor knockout mice reveals a link between TNF-alpha signaling and increased severity of 1918 pandemic influenza virus infection.

Authors:  Sarah E Belisle; Jennifer R Tisoncik; Marcus J Korth; Victoria S Carter; Sean C Proll; David E Swayne; Mary Pantin-Jackwood; Terrence M Tumpey; Michael G Katze
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Mast cell-induced lung injury in mice infected with H5N1 influenza virus.

Authors:  Yanxin Hu; Yi Jin; Deping Han; Guozhong Zhang; Shanping Cao; Jingjing Xie; Jia Xue; Yi Li; Di Meng; Xiaoxu Fan; Lun-Quan Sun; Ming Wang
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

3.  Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus.

Authors:  Alexandre A Boudreault; Hu Xie; Wendy Leisenring; Janet Englund; Lawrence Corey; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-24       Impact factor: 5.742

4.  Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus.

Authors:  Kevin B Walsh; John R Teijaro; Peter R Wilker; Anna Jatzek; Daniel M Fremgen; Subash C Das; Tokiko Watanabe; Masato Hatta; Kyoko Shinya; Marulasiddappa Suresh; Yoshihiro Kawaoka; Hugh Rosen; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-29       Impact factor: 11.205

5.  Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus.

Authors:  Lucy A Perrone; Kristy J Szretter; Jacqueline M Katz; Joseph P Mizgerd; Terrence M Tumpey
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

Review 6.  Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm.

Authors:  Kevin B Walsh; John R Teijaro; Hugh Rosen; Michael B A Oldstone
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

7.  Cytokines and neutrophils responses in influenza pneumonia.

Authors:  J M Bordon; S Uriarte; F W Arnold; R Fernandez-Botran; M Rane; P Peyrani; R Cavallazzi; M Saad; J Ramirez
Journal:  Infection       Date:  2013-04-16       Impact factor: 3.553

8.  Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus.

Authors:  Bo-Jian Zheng; Kwok-Wah Chan; Yong-Ping Lin; Guang-Yu Zhao; Chris Chan; Hao-Jie Zhang; Hong-Lin Chen; Samson S Y Wong; Susanna K P Lau; Patrick C Y Woo; Kwok-Hung Chan; Dong-Yan Jin; Kwok-Yung Yuen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-03       Impact factor: 11.205

9.  Treatment with the reactive oxygen species scavenger EUK-207 reduces lung damage and increases survival during 1918 influenza virus infection in mice.

Authors:  John C Kash; Yongli Xiao; A Sally Davis; Kathie-Anne Walters; Daniel S Chertow; Judith D Easterbrook; Rebecca L Dunfee; Aline Sandouk; Brett W Jagger; Louis M Schwartzman; Rolf E Kuestner; Nancy B Wehr; Karl Huffman; Rosalind A Rosenthal; Adrian Ozinsky; Rodney L Levine; Susan R Doctrow; Jeffery K Taubenberger
Journal:  Free Radic Biol Med       Date:  2013-10-17       Impact factor: 7.376

10.  Compartmental Model Suggests Importance of Innate Immune Response to COVID-19 Infection in Rhesus Macaques.

Authors:  Ericka Mochan; T J Sego; Lauren Gaona; Emmaline Rial; G Bard Ermentrout
Journal:  Bull Math Biol       Date:  2021-05-26       Impact factor: 1.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.